Zhihao Lu, Yang Chen, Dan Liu, Xi Jiao, Chang Liu, Yakun Wang, Zizhen Zhang, Keren Jia, Jifang Gong, Zhimin Yang, Lin Shen
{"title":"中国癌症研究和癌症治疗的现状","authors":"Zhihao Lu, Yang Chen, Dan Liu, Xi Jiao, Chang Liu, Yakun Wang, Zizhen Zhang, Keren Jia, Jifang Gong, Zhimin Yang, Lin Shen","doi":"10.1038/s41591-023-02655-3","DOIUrl":null,"url":null,"abstract":"The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country’s cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer. The authors discuss how screening strategies, treatment approaches and precision oncology are evolving in China and outline trends and priorities in the drug development and regulatory landscape.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"29 12","pages":"3022-3032"},"PeriodicalIF":58.7000,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The landscape of cancer research and cancer care in China\",\"authors\":\"Zhihao Lu, Yang Chen, Dan Liu, Xi Jiao, Chang Liu, Yakun Wang, Zizhen Zhang, Keren Jia, Jifang Gong, Zhimin Yang, Lin Shen\",\"doi\":\"10.1038/s41591-023-02655-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country’s cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer. The authors discuss how screening strategies, treatment approaches and precision oncology are evolving in China and outline trends and priorities in the drug development and regulatory landscape.\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":\"29 12\",\"pages\":\"3022-3032\"},\"PeriodicalIF\":58.7000,\"publicationDate\":\"2023-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41591-023-02655-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41591-023-02655-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
The landscape of cancer research and cancer care in China
The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country’s cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer. The authors discuss how screening strategies, treatment approaches and precision oncology are evolving in China and outline trends and priorities in the drug development and regulatory landscape.
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.